{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Famindr.com%2Fepisodes%2F121-amyloid-beta-aggregation-toxicity-part-1-january-2021-bXUmo7GM","width":444,"version":"1.0","type":"rich","title":"121 - Amyloid-beta Aggregation & Toxicity, Part 1: January 2021","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/9a8ef428-72db-47cb-a5cb-a6a258a13785/d140bd84-85a8-4b46-bbe4-33d4f19e691c/wordcloud-121-2.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/2bb8b347-e3a2-46f5-9f85-0caeb25b826f\" height=\"200\" width=\"100%\" title=\"121 - Amyloid-beta Aggregation &amp; Toxicity, Part 1: January 2021\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this episode, the first of a two-part mini series, Jacques runs through papers from January 2021 on amyloid-beta oligomers in aggregation and therapeutics strategies to target them. Tune in to hear about conformational changes, molecules that affect oligomerisation, oligomer conformation-specific treatment strategies and more! \n\nSections in this episode: \nOligomerization/Conformation, etc. (2:25) \nStrategies targeting oligomers (19:06) \n"}